Market Research Report
Global Tyrosine Kinase Inhibitors Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||763595|
|Published||Content info||115 Pages
Delivery time: 1-2 business days
|Global Tyrosine Kinase Inhibitors Market 2019-2023|
|Published: December 17, 2018||Content info: 115 Pages||
Strategic alliances to trend in the market. The growing prevalence of various diseases increases the demand for innovative therapeutics. TKI therapeutics are one of the most reliable therapeutic options for the treatment of cancer and age-related diseases such as RVO. Technavio' s analysts have predicted that the tyrosine kinase inhibitors market will register a CAGR of more than 8% by 2023.
Many TKI therapeutic candidates are gaining approval due to their high safety profile and efficacy. The therapeutics that are in last stage of development are expected to get marketing approval during forecast period.
Despite highly efficacious, TKIs are associated with a spectrum of side effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea.
For the detailed list of factors that will drive and challenge the growth of the tyrosine kinase inhibitors market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Novartis and Pfizer the competitive environment is quite intense. Factors such as the rising strategic alliances and the recent approvals of TKIs, will provide considerable growth opportunities to tyrosine kinase inhibitors manufactures. Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, Novartis, and Pfizer are some of the major companies covered in this report.